Ticagrelor

• CAT Number: A000779
• CAS Number: 274693-27-5
• Molecular Formula: C23H28F2N6O4S
• Molecular Weight: 522.6
• Purity: ≥95%
• Target: P2Y Receptor
• Solubility: >26.2mg/mL in DMSO
• Storage: -20°C
• IUPAC Name: (1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino]-5-propylsulfanyltriazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
• InChI: 1S/C23H28F2N6O4S/c1-2-7-36-23-27-21(26-15-9-12(15)11-3-4-13(24)14(25)8-11)18-22(28-23)31(30-29-18)16-10-17(35-6-5-32)20(34)19(16)33/h3-4,8,12,15-17,19-20,32-34H,2,5-7,9-10H2,1H3,(H,26,27,28)/t12-,15+,16+,17-,19-,20+/m0/s1
• InChIKey: OEKWJQXRCDYSHL-FNOIDJSQSA-N
• SMILES: CCCSC1=NC2=C(C(=N1)NC3CC3C4=CC(=C(C=C4)F)F)N=NN2C5CC(C(C5O)O)OCCO

Ticagrelor (CAT: A000779), also known as AZD-6140 and AR-C 126532XX, is a platelet aggregation inhibitor produced The drug was approved by FDA in 2011. Ticagrelor is an antagonist of the P2Y12 receptor. Like the thienopyridines prasugrel, clopidogrel and ticlopidine, ticagrelor blocks adenosine diphosphate (ADP) receptors of subtype P2Y12. This product is used for medical research and development and other scientific research purposes.

Reference

1: Ye M, Wang XF, Jia P, Zeng YJ. [Clinical effectiveness and safety of ticagrelor in patients after PCI because of acute non ST segment elevation myocardial infarction]. Zhonghua Yi Xue Za Zhi. 2017 Nov 21;97(43):3376-3379. doi: 10.3760/cma.j.issn.0376-2491.2017.43.003. Chinese. PubMed PMID: 29179275.
2: Jariwala P, Bhatia H, Kumar EAP. Sub-acute stent thrombosis secondary to ticagrelor resistance-Myth or reality!! Indian Heart J. 2017 Nov – Dec;69(6):804-806. doi: 10.1016/j.ihj.2017.10.012. Epub 2017 Oct 26. PubMed PMID: 29174265.
3: Liu HL, Wei YJ, Ding P, Zhang J, Li TC, Wang B, Wang MS, Li YT, Zhang JJ, Ren YH, Tang Q, Luo JP, Yang SL, Ma HY, Liu Y, Han W, Li Y, Jin ZG, Jin LM. Antiplatelet Effect of Different Loading Doses of Ticagrelor in Patients With Non-ST-Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: The APELOT Trial. Can J Cardiol. 2017 Dec;33(12):1675-1682. doi: 10.1016/j.cjca.2017.09.002. Epub 2017 Sep 12. PubMed PMID: 29173606.
4: Yang A, Pon Q, Lavoie A, Crawford JJ, Harenberg S, Zimmermann RH, Booker J, Kelly S, Lavi S, Cantor WJ, Mehta SR, Bagai A, Goodman SG, Cheema AN, Dehghani P. Long-term pharmacodynamic effects of Ticagrelor versus Clopidogrel in fibrinolytic-treated STEMI patients undergoing early PCI. J Thromb Thrombolysis. 2017 Nov 23. doi: 10.1007/s11239-017-1581-2. [Epub ahead of print] PubMed PMID: 29170875.
5: Ibrahim K, Goli RR, Shah R, Resar JR, Schulman SP, McEvoy JW. Effect of intravenous fentanyl on ticagrelor absorption and platelet inhibition among patients undergoing percutaneous coronary intervention: Design, rationale, and sample characteristics of the PACIFY randomized trial. Contemp Clin Trials. 2017 Nov 21;64:8-12. doi: 10.1016/j.cct.2017.11.011. [Epub ahead of print] PubMed PMID: 29170073.
6: Mrotzek SM, Rassaf T, Totzeck M. Ticagrelor Leads to Statin-Induced Rhabdomyolysis: A Case Report. Am J Case Rep. 2017 Nov 23;18:1238-1241. PubMed PMID: 29167415.
7: Motovska Z, Hlinomaz O, Kala P, Hromadka M, Knot J, Varvarovsky I, Dusek J, Jarkovsky J, Miklik R, Rokyta R, Tousek F, Kramarikova P, Svoboda M, Majtan B, Simek S, Branny M, Mrozek J, Cervinka P, Ostransky J, Widimsky P; PRAGUE-18 Study Group. One-year Outcomes of Prasugrel Versus Ticagrelor In Acute Myocardial Infarction Treated With Primary Angioplasty: The PRAGUE-18 Study. J Am Coll Cardiol. 2017 Nov 9. pii: S0735-1097(17)41524-5. doi: 10.1016/j.jacc.2017.11.008. [Epub ahead of print] PubMed PMID: 29154813.
8: Zocca P, van der Heijden LC, Kok MM, Löwik MM, Hartmann M, Stoel MG, Louwerenburg JW, de Man FHAF, Linssen GCM, Knottnerus IL, Doggen CJM, van Houwelingen KG, von Birgelen C. Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT. EuroIntervention. 2017 Nov 20;13(10):1168-1176. doi: 10.4244/EIJ-D-17-00634. PubMed PMID: 29151439.
9: Shang LL, Guo DD, Zhao HY, Quan AJ, Cao PG. Comparison of pharmacodynamic effects of ticagrelor vs prasugrel in type 2 diabetes mellitus patients with coronary heart disease. J Clin Pharm Ther. 2017 Nov 17. doi: 10.1111/jcpt.12651. [Epub ahead of print] PubMed PMID: 29150850.
10: Al-Salama ZT, Keating GM, Keam SJ. Ticagrelor: A Review in Long Term Secondary Prevention of Cardiovascular Events. Drugs. 2017 Nov 18. doi: 10.1007/s40265-017-0844-8. [Epub ahead of print] PubMed PMID: 29150806.